Showing 321 - 340 results of 395 for search '"Pharmaceutics"', query time: 0.06s Refine Results
  1. 321
  2. 322
  3. 323
  4. 324
  5. 325
  6. 326

    Astaxanthin-loaded brain-permeable liposomes for Parkinson’s disease treatment via antioxidant and anti-inflammatory responses by Thai-Duong Nguyen, Shristi Khanal, Eunhee Lee, Jinsol Choi, Ganesh Bohara, Nikesh Rimal, Dong-Young Choi, Soyeun Park

    Published 2025-02-01
    “…This study aimed to improve the pharmaceutical properties and neuroprotective effects of astaxanthin for Parkinson’s disease treatment by using lactoferrin-conjugated astaxanthin-loaded liposomes (Lf-ASX-LPs). …”
    Get full text
    Article
  7. 327

    Silica Nanoparticles Loaded With Selenium Quantum Dots Reduce Myocardial Ischemia-Reperfusion Injury by Alleviating Ferroptosis and Mitochondrial Dysfunction by Li T, Yang B, Liu X, Shi D, Wang Z, Chen Y, Shen C

    Published 2025-02-01
    “…Taixi Li,1,* Boshen Yang,1,* Xijian Liu,2 Dongmei Shi,1 Zhixiang Wang,1 Yizhi Chen,1 Chengxing Shen1 1Department of Cardiology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, People’s Republic of China; 2School of Chemistry and Chemical Engineering, Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Noncoding RNA, Shanghai Engineering Technology Research Center for Pharmaceutical Intelligent Equipment, Shanghai University of Engineering Science, Shanghai, 201620, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chengxing Shen, Department of Cardiology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, People’s Republic of China, Email shencx@sjtu.edu.cnPurpose: Myocardial ischemia-reperfusion (IR) injury, a significant challenge in cardiovascular treatment, is primarily driven by ferroptosis and mitochondrial dysfunction. …”
    Get full text
    Article
  8. 328
  9. 329

    The Impacts of Breakthrough Drug Classes on Total Healthcare Expenditures by Zeynal Karaca, Steven N. Wiggins

    Published 2016-02-01
    “…**Background:** Pharmaceutical firms spend billions of dollars developing new therapies, which are often sold at a substantial premium over older therapies. …”
    Get full text
    Article
  10. 330
  11. 331
  12. 332
  13. 333
  14. 334
  15. 335
  16. 336

    Acceptability and feasibility of pre-exposure prophylaxis for bacterial STIs: a systematic review. by Julie-Anne Carroll, Amy B Mullens, Sarah Warzywoda, Philip R A Baker, Meika Stafford, Faye McMillan, Jacintha Manton, Daniel Demant

    Published 2025-01-01
    “…Similarly, the perspectives of populations beyond GBMSM have been omitted, and there is little understanding of the impact of their differing socio-cultural contexts around sex-related behaviour and Western pharmaceutical healthcare interventions on their acceptance and uptake.…”
    Get full text
    Article
  17. 337
  18. 338
  19. 339
  20. 340

    Pain in pancreatitis: issue and ways out by A. V. Okhlobystin

    Published 2012-02-01
    “…Pancreatic enzymes represents the basis of pharmaceutical treatment nowadays. Their application is based on multiple negative feedback mechanisms involved in pancreatic secretion regulation. …”
    Get full text
    Article